Lisata Therapeutics
Biopharmaceutical company in New Jersey, United States From Wikipedia, the free encyclopedia
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.[1]
| Company type | Public |
|---|---|
| Nasdaq: LSTA | |
| Industry | Biopharmaceuticals |
| Headquarters | Basking Ridge, New Jersey, United States |
Key people | David J. Mazzo (CEO) |
| Website | lisata |
In 2019, the FDA granted their product, certepetide (also known as iRGD and CEND-1), orphan drug status in pancreatic cancer, followed by a Fast track (FDA) status in 2022.[2] Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.[3]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.